Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.

Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV

The Journal of clinical endocrinology and metabolism26 Dec 2007Cited by 183 (Europe PMC)

PMID18160462DOI10.1210/jc.2007-0711PepBankPUB-18160462

Source link PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialEfficacy outcome
In previously treated women with osteoporosis, bone formation markers increased after one month of teriparatide in all prior-treatment groups.
In plain wordsTeriparatide increased bone formation markers compared with baseline in women previously treated with antiresorptive drugs.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone formation markers
Study
n = 245
Comparator
Baseline
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/d · 2 yrAs given in this study (human).
Source sentences
Summary
Significant increases in bone formation markers occurred in all groups after 1 month of teriparatide treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
The present secondary analysis examined the effects of 2 yr of open-label teriparatide in women previously treated with antiresorptive drugs for at least 1 yr.
Summary · context
A subgroup of 245 women with osteoporosis who had 2 yr of teriparatide treatment were stratified by previous predominant antiresorptive treatment into four groups: alendronate (n=107), risedronate (n=59), etidronate (n=30), and non-bisphosphonate (n=49).
Report a problemFND-1816046201
02HumanNon-randomized trialEfficacy outcome
In previously treated women with osteoporosis, lumbar spine BMD increased at all visits during teriparatide treatment.
In plain wordsTeriparatide increased spine bone density compared with baseline in previously treated women.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD
Study
n = 245
Comparator
Baseline
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/d · 2 yrAs given in this study (human).
Source sentences
Summary
Lumbar spine BMD increased at all visits, whereas a transient decrease in hip BMD, which was subsequently reversed, was observed in all groups.
2 context sentences(design, population, supporting numbers)
Summary · context
The present secondary analysis examined the effects of 2 yr of open-label teriparatide in women previously treated with antiresorptive drugs for at least 1 yr.
Summary · context
A subgroup of 245 women with osteoporosis who had 2 yr of teriparatide treatment were stratified by previous predominant antiresorptive treatment into four groups: alendronate (n=107), risedronate (n=59), etidronate (n=30), and non-bisphosphonate (n=49).
Report a problemFND-1816046202
03HumanNon-randomized trialEfficacy outcome
In previously treated women with osteoporosis, hip BMD decreased transiently and subsequently recovered during teriparatide treatment.
In plain wordsDuring teriparatide treatment, hip bone density first decreased and then recovered in previously treated women.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedHip BMD trajectory
Study
n = 245
Comparator
Baseline
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg/d · 2 yrAs given in this study (human).
Source sentences
Summary
Lumbar spine BMD increased at all visits, whereas a transient decrease in hip BMD, which was subsequently reversed, was observed in all groups.
2 context sentences(design, population, supporting numbers)
Summary · context
The present secondary analysis examined the effects of 2 yr of open-label teriparatide in women previously treated with antiresorptive drugs for at least 1 yr.
Summary · context
A subgroup of 245 women with osteoporosis who had 2 yr of teriparatide treatment were stratified by previous predominant antiresorptive treatment into four groups: alendronate (n=107), risedronate (n=59), etidronate (n=30), and non-bisphosphonate (n=49).
Report a problemFND-1816046203

Studies that did not test the peptide alone4

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women receiving teriparatide, BMD responses were similar across prior antiresorptive treatment groups.
In plain wordsBone density responses to teriparatide were similar across previous treatment groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBMD response by previous treatment
Study
n = 245
Comparator
Other prior antiresorptive groups
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
BMD responses were similar in all previous antiresorptive groups.
2 context sentences(design, population, supporting numbers)
Summary · context
The present secondary analysis examined the effects of 2 yr of open-label teriparatide in women previously treated with antiresorptive drugs for at least 1 yr.
Summary · context
A subgroup of 245 women with osteoporosis who had 2 yr of teriparatide treatment were stratified by previous predominant antiresorptive treatment into four groups: alendronate (n=107), risedronate (n=59), etidronate (n=30), and non-bisphosphonate (n=49).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1816046204
05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studySafety outcome
In previously treated women, teriparatide adverse events resembled those reported in treatment-naive women with osteoporosis.
In plain wordsIn previously treated women, teriparatide adverse events were similar to those reported in treatment-naive women.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeTreatment-emergent adverse events
Study
n = 245
Comparator
Treatment-naive postmenopausal women with osteoporosis treated with teriparatide, as reported elsewhere
Analysis
Secondary
Outcome group
Adverse events · Whole body
Source sentences
Summary
Treatment-emergent adverse events were similar to those reported in treatment-naive postmenopausal women with osteoporosis treated with teriparatide.
2 context sentences(design, population, supporting numbers)
Summary · context
The present secondary analysis examined the effects of 2 yr of open-label teriparatide in women previously treated with antiresorptive drugs for at least 1 yr.
Summary · context
A subgroup of 245 women with osteoporosis who had 2 yr of teriparatide treatment were stratified by previous predominant antiresorptive treatment into four groups: alendronate (n=107), risedronate (n=59), etidronate (n=30), and non-bisphosphonate (n=49).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1816046207
06HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women receiving teriparatide, previous etidronate users had a larger spine BMD increase than other prior-treatment groups.
In plain wordsPrevious etidronate users had larger spine bone density increases with teriparatide than other prior-treatment groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSpine BMD response after etidronate
Study
n: not reported in source
Comparator
Other prior antiresorptive groups
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Previous etidronate users showed a higher increase at the spine but not at the hip BMD.
2 context sentences(design, population, supporting numbers)
Summary · context
The present secondary analysis examined the effects of 2 yr of open-label teriparatide in women previously treated with antiresorptive drugs for at least 1 yr.
Summary · context
A subgroup of 245 women with osteoporosis who had 2 yr of teriparatide treatment were stratified by previous predominant antiresorptive treatment into four groups: alendronate (n=107), risedronate (n=59), etidronate (n=30), and non-bisphosphonate (n=49).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1816046205
07HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women receiving teriparatide, previous etidronate users did not show a greater hip BMD increase.
In plain wordsPrevious etidronate users did not have greater hip bone density increases with teriparatide than other prior-treatment groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeHip BMD response after etidronate
Study
n: not reported in source
Comparator
Other prior antiresorptive groups
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Previous etidronate users showed a higher increase at the spine but not at the hip BMD.
2 context sentences(design, population, supporting numbers)
Summary · context
The present secondary analysis examined the effects of 2 yr of open-label teriparatide in women previously treated with antiresorptive drugs for at least 1 yr.
Summary · context
A subgroup of 245 women with osteoporosis who had 2 yr of teriparatide treatment were stratified by previous predominant antiresorptive treatment into four groups: alendronate (n=107), risedronate (n=59), etidronate (n=30), and non-bisphosphonate (n=49).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1816046206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.